Revelation Biosciences reports Gemini induces dose-dependent IL-10 increases up to 309-fold in Phase 1

REVELATION BIOSCIENCES, INC.

Gemini induced statistically significant (p<0.05) dose-dependent IL-10 increases: 27-fold (low), 162-fold (mid), 309-fold (high) vs placebo at 2 hours.
No significant increase in pro-inflammatory IL-1b and TNF-a, confirming TLR4 binding unique to Gemini.
Data consistent with prior preclinical acute kidney injury models; supports potential in preventing AKI after cardiac surgery.
Company plans to initiate Phase 1b study in late 2024.
CEO James Rolke highlighted potential to fine-tune innate immune response and speed healing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.